Question 1: What is to be distributed?
Answer: Vitrolife’s transplantation business, which is run in the subsidiary Xvivo Perfusion AB (”Xvivo”) and its subsidiaries.
Question 2: What are the reasons for the distribution of Xvivo?
Answer: Fertility and Transplantation are in different phases of development and the Board considers that separate ownership increases the strategic opportunities that each company can utilize for increased added value
Question 3: How is the distribution done?
Anwer: The distribution means that the Vitrolife shareholders automatically will receive one share in Xvivo for each share that they own in Vitrolife.
Questions 4: What do I as shareholder need to do in order to receive the distribution?
Answer: Nothing. The shares will automatically be booked in each shareholder’s VPC account.
Question 5: Where and when will the Xvivo shares be traded?
Answer: Xvivo will be listed on NASDAQ OMX First North and trade will begin on October 8.
Question 6: What is the time plan for the distribution?
Anwers: The last day for trade in Vitrolife shares with entitlement to distribution of shares in Xvivo is September 26. The record day is October 1. It is estimated that the Xvivo shares will have been booked in each shareholder’s VPC account by October 4. Trade in Xvivo shares on NASDAQ OMX First North will begin on October 8. Before the listing, Xvivo will publish a description of the company containing detailed information about the company.
Question 7: What will be the allotment of the cost of acquisition for the shares?
Answer: Allotment of the cost of acquisition for the shares will be decided by the Swedish Tax Agency and will be published on Vitrolife’s and Xvivo’s websites.
Question 8: What will be the tax consequences of the distribution?
Anwer: The distribution of the shares in Xvivo will be done in accordance with “Lex Asea”. The distribution will not result in any tax effect for present Vitrolife shareholders as long as they remain as owners of Xvivo. Allotment of the cost of acquisition for the shares will be decided by the Swedish Tax Agency and will be published on Vitrolife’s and Xvivo’s websites.
Question 9: What is the value of Xvivo in Vitrolife AB at the time of distribution?
Answer: The book value of Xvivo Perfusion AB after the shareholder contribution is estimated to 65.518.757 SEK, which corresponds to a value of 3,35 SEK per share.
Question 10: What will be the market value of Vitrolife and Xvivo after the distribution?
Answer: The value is determined by the market. Vitrolife is traded without entitlement to distribution of shares in Xvivo from September 27 and trade in Xvivo on NASDAQ OMX First North will begin on October 8.